medigraphic.com
ISSN 0188-9796 (Print)

2001, Number 1

<< Back Next >>

Rev Endocrinol Nutr 2001; 9 (1)

Endocrinological perspectives and current events in management of postmenopausal women

Vadillo BM, Bañuelos ÁR, Caracas PN, González BD, García LLE

Language: Spanish
References: 57
Page: 16-25
PDF size: 93.73 Kb.


ABSTRACT

Menopause constitutes one of the most important health problems at the present time in all countries. The lack of hormone replacement therapy (HRT) affects the correct functioning of various systems of the human body such as the central nervous system, cardiovascular, urinary, digestive and skeletal systems. Its correct management is focused primarily to avoid further damage to these systems with more importance to the cardiovascular systems and bone. Among the therapeutic modalities considered are: estrogens, progestins, tibolone, raloxifene calcitonin, alendronates, parathyroid hormone and vitamin D. With regards to the gastrointestinal system we have found alterations in the serum levels of gastrin in the basal state and in response to stimuli. Estrogens and progestins are the most important part of the medical treatment of menopause and we consider that their administration represents the founding of a complete and integrated management of women in this stage of their lives, in an effort to try to diminish the great problem that osteoporosis represents not only to women but to all human beings.


REFERENCES

  1. De Groot LJ. Endocrinology. 2a. Edition WB Saunders Company 1989: 2009-2018.

  2. García UA, Nava LE, Malacara JM. La edad de la menopausia en la población urbana de la Cd. de León Gto. Rev Invest Med 1989; 149: 133-138.

  3. Conapo. Fuente de estimaciones y Proyectos del Consejo Nacional de Población 2000, México.

  4. Bewley S, Bewley TH. Drug dependence with estrogens replacement therapy. The Lancet 1992; 339: 290-291.

  5. Ravinkar V. Physiology and treatment of hot flushes. Obstet Gynecol 1990; 75: 35-40.

  6. Dufourny L, Warembourg M. Estrogen modulation of neuropeptides: somatostatin, neurotensin and substance P, in the ventrolateral and arcuate nuclei of the female guinea pig. Neurosci Res 1999; 313(3): 223-228.

  7. Díaz Véliz G, Benavides MS, Butrón S, Dussaubat N, Mora S. Behavioral effect of dopamine agonist and antagonist: influence of estrogen cycle, ovariectomy and estrogen replacement in rats. Pharmacol Biochem Behav 1999; 62(1): 21-29.

  8. Stial M, Dupont A, Labre F. Changes in plasma lipoprotein and apolipoprotein composition in relation to oral versus percutaneus administration of estrogen alone or in cyclic association with uyrogestan in menopausal women. Endocrinol and Metab 1991; 73: 273-278.

  9. Ansbacher R. The pharmacokinetics and efficacy of different estrogens are not equivalent. Am J Obstet Gynecol 2001; 184: 255-263.

  10. Hammond CB, Jelovsek FR, Lee KL, Creasman WT, Parker RT. Effects of long term estrogen replacement therapy: I-Metabolic effects. Am J Obstet Gynecol 1979; 133: 525-536.

  11. Barret CE, Brown V, Turner J, Austin M, Criqui MH. Heart disease risk factors and hormone use in postmenopausal women. JAMA 1979; 241(20): 2167-2169.

  12. Wren BO, Routledge AD. The effect of type and dose of oestrogen on the blood pressure of postmenopausal women. Maturitas 1983; 5(2): 135-142.

  13. Lind T, Cameron EC, Hunter WM, Leon C, Moran PF, Oxley A, Gerrard J, Lind UC. A prospective controlled trial of six forms of hormone replacement therapy given to postmenopausal women. Br J Obstet Gynaecol 1979; 86(Suppl 3): 1-29.

  14. Raz R, Stamm W. A controls trials of intravaginal estriol in postmenopausal women with recurrent urinary tract infections. N Engl J Med 1993; 329: 753-756.

  15. Guerra AL, González BD. Tesis: Climaterio. Dinámica de gastrina en mujeres en edad fértil y en climatéricas pre y posestrogenoterapia. Depto. Clínico de Endocrinología HECMR, (IMSS), 1991.

  16. Bañuelos-Alvarez R, González-Bárcena D. Tesis: respuesta de gastrina ante una carga bucal de calcio en mujeres climatéricas pre y posterapia con estrógenos transdérmicos. Depto Clínico de Endocrinología HECMR (IMSS), 1992.

  17. Vadillo BM, González BD. Indicaciones y contraindicaciones del tratamiento hormonal en la perimenopausia. Rev Med Inter Mex 1992; 8(3): 148.

  18. Dempster D, Lindsay R. Pathogenesis of osteoporosis. Lancet 1993; 341: 797-805.

  19. Riggs L, Melton J. The prevention and treatment of osteoporosis. N Engl J Med 1992; 327: 620-626.

  20. Compston JE. Osteoporosis. Clinical Endocrinology 1990; 33: 653-682.

  21. Joborn C, Ljunghalls L. Skeletal responsiveness to parathyroid hormone in healthy females relationship to menopause and estrogen replacement. Clin Endocrinol 1991; 34: 335-339.

  22. Corpas E, Harman M, Blackman R. Human growth hormone and human aging. Endocrine Rev 1993; 14: 20-32.

  23. Kaiser F. Aging and malnutrition: Growth hormone therapy shows promise. Geriatrics 1992; 47: 88-90.

  24. García de León LE, Vadillo Buenfil M, González BD. Tesis. Influencia de la administración transdérmica de 17 b Estradiol sobre la liberación de la hormona de crecimiento en mujeres climatéricas. Depto Clínico de Endocrinología, HECMR (IMSS); 1994.

  25. Fonseca E, Ochoa R, Galvan R, Hernández M, Mercado M, Zarate A. Increased serum levels of growth hormone and IGF-1 associated with simultaneous decrease of circulating insulin in postmenopausal women receiving HRT. Menopause 1999; 6(1): 56-60.

  26. Widermann Ch, Niedermuhlbichler, Beimpold H, Braunsteiner H. In vitro activation of neutrophils of the aged by recombinant human growth hormone. J Infect Dis 1991; 164: 1017-1020.

  27. Ryu H, Lee JH, Kim KS, Jeong SM, Kim PH, Chung HT. Regulation of neutrophil adhesion by pituitary growth hormone accompanies tyrosine phosphorylation of Jak2, p125FAK, and paxillin. J Immunol 2000; 165(4): 2116-2123.

  28. Casanueva F. Physiology of growth hormone secretion and action. Endocrinol & Metab Clinics of North Am 1992; 21: 483-509.

  29. Mauras N, Rogal AD, Veldhuis JD. Increased GH production rates after low dose estrogen therapy in prepubertal girls with Turner Syndrome. Pediatric Research 1990; 28: 626-630.

  30. Roubenoff R, Rall LC, Veldhuis JD, Kehayias JJ, Rosen C, Nicolson M, Lundgren N, Reichlin S. The relationship between growth hormone kinetics and sarcopenia in postmenopausal women: the role of fat mass and leptin. J Clin Endocrinol Metab 1998; 83(5): 1502-1506.

  31. 3l. Rudman D, Feller A, Cohon L, Shetty K, Rudman I, Draper M. Effects of human growth hormone on body composition in elderly men. Horm Res 1991; 36 Suppl 1: 73-81.

  32. Kassen M, Brixen K, Moselkill, Blum WF, FIyubjery A. Effects of growth hormone treatment on serum levels of Insulin- like growth factors (IGFs) and IGF binding proteins 1-4 in postmenopausal women. Clin Endocrinol (OXF) 1998; 49(6): 747-756.

  33. Moe KE, Prinz PN, Larsen LH, Vitiello MV, Reed SO, Merriam GR. Growth hormone in postmenopausal women after long-term oral estrogen replacement therapy. J Gerontol A Biol Sci Med Sci 1998; 53(2): B117-124.

  34. Chan JM, Stampfer MJ, Giovannucci, Gann PH, Ma J, Wilkinson P, Hennekens CH, Pollak M. Plasma Insulin-Like Growth Factor-1 and Prostate Cancer Risk: A Prospective Study. Science 1998; 279: 563-566.

  35. Monolagas SC. Cytokines, hematopoyesis, osteoclastogenesis and estrogens. Calcif Tissue Int 1992; 50: 199-202.

  36. Colacurci N, Mele D, De Franciscis P, Costa V, Fortunato N, De Seta L. Effects of tibolone on the breast. Eur J Obstet Gynecol Reprod Biol 1998; 80(2): 235-238.

  37. Ettinger B, Black DM, Mitlak BH, Knickerbocker RK, Nickelsen T, Genant HK, Christiansen C, Delmas PD, Zanchetta JR, Stakkestad J, Gluer CC, Krueger K, Cohen FJ, Eckert S, Ensrud KE, Avioli LV, Lips P, Cummings SR. Reduction of vertebral fracture risk in postmenopausal women with osteoporosis treated with raloxifene: results from a 3-years randomized clinical trial. Multiple outcomes of Raloxifene Evaluation (MORE) Investigators. JAMA 1999; 282: 637-645.

  38. Gennari C, Agnusdei D, Camporeale A. Use of calcitonin in the treatment of bone pain associated with osteoporosis. Calcif Tissue Int 1991; 49(Suppl 2): S9-S13.

  39. Liberman UA, Weiss SR, Broll J, Minne HW, Quan H, Bell NH, Rodriquez-Portales J, Downs RW Jr., Dequeker J, Favus M, Seeman E, Recker RR, Capizzi T, Santora AC. II, Lombardi A, Shah R, Hirsch LJ, Karpf DB. Effect of oral alendronate on bone mineral density and the incidence of fractures in postmenopausal osteoporosis. N Engl J Med 1995; 333: 1437-1443.

  40. Black DM, Cummings SR, Karpf DB, Cauley JA, Thompson DE, Nevitt MC, Bauer DC, Genant HK, Haskell WL, Marcus R, Ott SM, Torner JC, Quandt SA, Reiss TF, Ensrud KE. Randomized trial of effect of alendronate on risk of fracture in women with existing vertebral fractures. Lancet 1996; 348: 1535-1541.

  41. Cummings SR, Black DM, Thompson DE, Applegate WB, Barrett-Connor E, Musliner TA, Palermo L, Prineus R, Rubin SM, Scott JC, Vogt T, Wallace R, Yates AJ, LaCroix AZ. Effect of alendronate on risk of fracture in women with low bone density but without vertebral fractures. JAMA 1998; 280: 2077-2082.

  42. Pols HAP, Felsenberg D, Hanley DA, Stepan J, Munoz-Torres M, Wilkil TJ, Qin-sheng G, Galich AM, Vandor-mael K, Yates AJ. Stych: Multinational, placebo-controlled, randomized trial of the effects of alendronate on bone density and fracture risk in postmenopausal women with low bone mass: results of the FOSIT study. Osteoporos 1999; 9: 461-468.

  43. Hosking D, Chilvers CED, Christiansen C, Ravn P, Wasnich R, Ross P, McClung M, Balske A, Thompson D, Daley M, Yates AJ. Prevention of bone loss with alendronate in postmenopausal women under 60 years of age. N Engl J Med 1998; 338: 485-492.

  44. McClung M, Clemmesen B, Daifotis A, Gilchrist NL, Eisman J, Weinstein RS, El Hajj Fuleihan G, Reda C, Yates AJ, Ravn P. Alendronate prevents postmenopausal bone loss in women without osteoporosis: a double-blind, randomized, controlled trial. Ann Intern Med 1998; 128: 253-261.

  45. Schnitzer T, Bone HG, Crepaldi G, Adami S, McClung M, Kiel D, Felsenberg D, Recker RR, Tonino RP, Roux C, Pinchera A, Foldes AJ, Greenspan SL, Levine MA, Emkey AC, Santora II AC, Kaur A, Thompson DE, Yates J, Orloff JJ. Para el grupo de estudio de alendronato una vez a la semana. Equivalencia terapéutica de 70 mg de alendronato una vez a la semana y 10 mg de alendronato diarios en el tratamiento de la osteoporosis. Aging Clin Exp Res 2000; 12: 1-12.

  46. Rodan GA, Seedor JG, Balena R. Preclinical pharmacology of alendronate. Osteoporos Int Suppl 1993; (3): S7-12.

  47. Khan SA, Kanis JA, Vasikaran S, Kline WF, Matuszewski BK, McCloskey EV, Beneton MN, Gertz BJ, Sci berras DG, Holland SD, Orgee J, Coombes GM, Rogers SR, Porras AG. Elimination and biochemical responses to intravenous alendronate in postmenopausal osteoporosis. J Bone Miner Res l997; 12: 1700-1707.

  48. Gertz BJ, Holland SD, Kline WF, Matuszewski BK, Porras AG. Clinical pharmacology of alendronate sodium. Osteoporos Int Suppl 1993; (3): S13-16.

  49. Porras AG, Holland SD, Gertz BJ. Pharmacokinetics of alendronate. Clin Pharmacokinet 1999; 36: 315-328.

  50. Peter CP, Handt LK, Smith SM. Esophageal irritation due to alendronato sodium tablets: possible mechanisms. Dig Dis Sci 1998; 43: 1998-2002.

  51. Bone HG, Adami S, Rizzoli R, Favus M, Ross PD, Santora A, Prahalada S, Daifotis A, Orloff J, Yates AJ. Weekly administration of alendronate: rationale and plan for clinical assessment. Clin Ther 2000; 22: 15-28.

  52. Shen V, Dempster DW, Mellish RWE, Birchman R, Horbert W, Lindsay R. Effects of combined and separate intermittent administration of low - dose human parathyroid hormone fragment (1-34) and 17-estradiol on bone histomorphometry in ovariectomized rats with established osteopenia. Calcif Tissue Int 1992; 50: 214-220.

  53. Hesch RD, Busch U, Prokop M, Delling G, Rittinghaus EF. Increase of vertebral density by combination therapy with pulsatile 1-38hPTH and sequential addition of calcitonin nasal spray in osteoporotic patients. Calcif Tissue Int 1989: 176-180.

  54. Bradbeer JN, Arlot ME, Meunier PJ, Reeve J. Treatment of osteoporosis with parathyroid peptide (hPTH 1-34) and oestrogen: increase in volumetric density of iliac cancellous bone may depend on reduced trabecular spacing as well as increased thickness of packets of newly formed bone. Clin Endocrinol 1992; 37: 282-289.

  55. Reeve J, Arlot ME, Bradbeer JN, Hesp R, Mcally E, Meunier PJ, Zanelli J. Human parathyroid peptide treatment of vertebral osteoporosis. Osteoporosis Int 1993; 3 Suppl 1: 199-203.

  56. Reichel H, Koeffler HP, Norman AW. The role of vitamin D endocrine systems in health and disease. New Engl J Med 1989: 980-991.

  57. Bellantoni MF, Vittone J, Campfield AT, Bass KM, Harman M, Blackman MR. Effects of oral versus transdermal estrogen on the growth hormone/insulin-lilke growth factor I axis in younger and older postmenopausal women: A clinical Research Center Study. J Clin Endocrinol Metab 1996; 81: 2848-2853.




2020     |     www.medigraphic.com